Author/Editor		Jazbec, Janez; Dolžan, Vita; Debeljak, Maruša; Aplenc, Richard; Jereb, Berta
Title		Vpliv polimorfizma glutationskih S transferaz na pojav sekundarnih novotvorb po zdravljenju levkmije v otroštvu
Translated title		The effect of polymorphism in glutathione S-transferases on the developing second malignant neoplasms after leukemia treatment in childhood
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 73, št. Suppl 1
Publication year		2004
Volume		str. I-19-22
Language		slo
Abstract		Background. Survivors of childhood leukemia have an increased risk of developing second malignant neoplasms and specific treatment factors such as alkylating agents, topoisomerase inhibitors and radiation have been associated with their occurrence. Genetic polymorphism in drug-metabolizing enzymes may result in impared detoxification of chemotherapeutics and may lead to increased risk for cancer. Methods. To test if polymorphism in glutathione S-transferases (GST) genes is associated with occurrence of secondary malignant neoplasms, we compared GSTM1, GSTT1 and GSTP1 genotypes among 16 patients treated for childhood leukemia in whom second neoplasm occurred and matched the control group. Results. GSTM1 null genotype was found in 44% of patients with second neoplasms and in 50% in control group (p = 0.768), GSTT1 null genotype in 19% of cases and in 29% of controls (p = 0.729) and GSTP1105Ile/ile in 50% of cases and 37% of controls (p = 0.537). Differences in distribution of GST genotypes in patients with second neoplasrrts after childhood leukemia, compared to a matched control group of patients were not statistically significant. Conclusions. In our study we were not able to show relation between GST genotype and occurrence of second neoplasms after the childhood acute leukemia.
Summary		Izhodišča. Povečano tveganje za nastanek sekundarnih novotvorb po zdravljenju levkemije v otroštvu je delno povezano tudi s specifičnimi elementi zdravljenja, kot so alkilirajoči agensi inhibitorji topoizomeraz in radioterapija. Genski polimorfizem encimov, ki so vpleteni v metabolizem zdravil, lahko vpliva na detoksifikacijo kemoterapevtikov in prek tega mehanizma povečuje nevarnost za nastanek sekundarnih novotvorb. Metode. Za preveritev hipoteze, da je polimorfizem genov glutationskih S transferaz (GST) povezan z zvečanim tveganjem za nastanek sekundarnih novotvorb, smo primerjali genotipe GSTT1, GSTM1 in GSTP1 16 bolnikov, pri katerih je bila po zdravljenju akutne levkemije v otroštvu odkrita sekundarna novotvorba z genotipi pri kontrolni skupini. Rezultati. Genotip GSTM1 null smo našli pri 44% bolnikov s sekundarno novotvorbo in pri 50% kontrol (p = 0, 76), genotip GSTT1 null pri 19% primerov in 29% kontrol (p = 0, 73) in GSTP1105Ile/Ile v 50% primerov in 37% kontrol (p = 0,53). Zaključki. Razlike v distribuciji GST genotipov pri bolnikih s sekundarnimi novotvorbami po zdravljenju akutne levkemije v otroštvu so v primerjavi s kontrolno skupino statistično neznačilne.
Descriptors		LEUKEMIA GLUTATHIONE TRANSFERASES NEOPLASMS, SECOND PRIMARY CHILD GENOTYPE POLYMORPHISM (GENETICS)